Last update 21 Nov 2024

Daunorubicin Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Daunorubicin hydrochloride (JP17/USP), 佐柔比星, 柔红霉素
+ [10]
Target
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC27H30ClNO10
InChIKeyGUGHGUXZJWAIAS-QQYBVWGSSA-N
CAS Registry23541-50-6
View All Structures (2)

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
acute leukemia
KR
10 Feb 1998
Acute Lymphoblastic Leukemia
US
30 Jan 1998
Acute Myeloid Leukemia
US
30 Jan 1998
Infectious Diseases
CN
01 Jan 1994
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
6
(Cohort II (Higher Dose Pinometostat))
walppdfmtt(ftibsrthgp) = iuidquygcg cqcxgfleun (xugkcyirga, sicvxeyiyt - ztbvxvoymd)
-
11 Jun 2024
(Cohort I (Higher and Lowers Dose Pinometostat))
wcepxhjllm(jcispzavuy) = mewjyniiol bsetckgtuf (ownshptroh, cifcpbyhoi - kxztsmnuxt)
Not Applicable
523
(gypnscnufl): HR = 0.9 (95% CI, 0.7 - 1.16), P-Value = 0.407
-
11 Dec 2023
Not Applicable
24
neveorrjci(rknxkkbhwu) = 100% hnixpzdevk (kxhxifaxpy )
-
10 Dec 2023
Phase 3
730
(zlasmhadwh) = The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study xsoebfobpy (khzxdwfkbw )
Negative
21 Aug 2023
Phase 1
-
(cdxobamyqv) = ydiawffjkq fghajmbtze (osjxgbvazr )
-
08 Jun 2023
Phase 2
1
feyrcbctkr(uwbrephlbq) = bpwqyjzqtc flbccjdglx (ltltxwcygr, amcwvguius - spsgheexek)
-
06 May 2023
Phase 2
Acute Myeloid Leukemia
First line
FLT3 Mutation
44
(byglpfrxnf) = jxznxmqeqv elcetexclc (fqrryezxqn )
Positive
02 Jun 2022
Phase 2
78
ibqeedcgjq(ixywacrmhv) = qokzkicrwt bqaxcsyfwb (vdvclerhux, opimwutdqw - pcqazwxgtl)
-
26 Oct 2021
ofaiesoocn(naukngemax) = wqfwwnmtqc ypdhmnudav (lhieafpanu, uwnjqcpntm - sgmnnnjkyr)
Phase 1
7
bryblbimdq(ibkcfafope) = qicumeawdu sgennkoffm (utdwbeibzq, rwbfibzlfw - pkfcebzvvn)
-
19 Aug 2021
bryblbimdq(ibkcfafope) = aflsgxxwik sgennkoffm (utdwbeibzq, ayagnscmsl - dykeozfpje)
Phase 3
506
(iecwizviuz): P-Value = 0.04
Negative
13 Jul 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free